A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT04208061
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT04208373
- Locations
- π§πͺ
SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg), Antwerpen, Belgium
A Study of JNJ-70033093 and Digoxin in Healthy Participants
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT04206488
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH)
- Conditions
- Hypertension, Pulmonary
- Interventions
- Other: Blood Sample
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 908
- Registration Number
- NCT04193046
- Locations
- π«π·
CHU de Brest - Hopital de la Cavale Blanche, Brest, France
π©πͺUniversitatsklinikum Schleswig Holstein, Luebeck, Germany
π΅π±Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego, Lublin, Poland
A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 76
- Registration Number
- NCT04185051
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-12-02
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 419
- Registration Number
- NCT04181827
- Locations
- π¬π§
Kings College Hospital, London, United Kingdom
π¬π§Christie Hospital, Manchester, United Kingdom
π¬π§Freeman Hospital, Newcastle Upon Tyne, United Kingdom
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-GuΓ©rin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 107
- Registration Number
- NCT04172675
- Locations
- π¦π·
Hospital Italiano de Buenos Aires, Ciudad Autonoma de, Argentina
π¦π·Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Cordoba, Argentina
π¦π·Centro Urologico Profesor Bengio, Cordoba, Argentina
A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT04154774
- Locations
- πΊπΈ
Homestead Associates in Research Inc, Homestead, Florida, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
πΊπΈGenesis Clinical Research, Tampa, Florida, United States
A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 440
- Registration Number
- NCT04147338
- Locations
- π©πͺ
CRS Clinical Research Services, Mannheim, Germany
πΊπΈCelerion, Tempe, Arizona, United States
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 237
- Registration Number
- NCT04133636
- Locations
- πΊπΈ
University Of California San Diego, San Diego, California, United States
πΊπΈUniversity of California San Francisco, San Francisco, California, United States
πΊπΈYale University School Of Medicine, New Haven, Connecticut, United States